Abstract
A prospective trial with concurrent controls was designed to assess the effects of specific active immunotherapy in patients receiving intermittent cytotoxic chemotherapy (DTIC + Vincristine) as an adjuvant to surgery in Stage IIB malignant melanoma. The treated group received monthly irradiated allogeneic melanoma cells and BCG, and the controls BCG only. Sixteen patients in the treatment arm had a median relapse-free interval of 5 months, compared to 8 months in 12 controls given chemotherapy and BCG, and because of this we felt that continuation of the study was unjustified on ethical grounds. Although all the controls who relapsed did so at distant sites, 7/11 patients given specific active immunotherapy relapsed initially within the lymphatic drainage area of the primary tumour. The median intervals from starting treatment to relapse at distant sites, and the median survival were identical in the 2 groups. We conclude that immunotherapy comprising irradiated allogenic melanoma cells as employed in this study does not prolong survival in surgically treated Stage IIB malignant melanoma and may even promote early, local relapse.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Currie G. A., McElwain T. J. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer. 1975 Feb;31(2):143–156. doi: 10.1038/bjc.1975.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gutterman J. U., Mavligit G., McBride C., Frei E., 3rd, Freireich E. J., Hersh E. M. Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet. 1973 Jun 2;1(7814):1208–1212. doi: 10.1016/s0140-6736(73)90526-6. [DOI] [PubMed] [Google Scholar]
- Hedley D. W., McElwain T. J., Currie G. A. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy. Eur J Cancer. 1977 Oct;13(10):1169–1173. doi: 10.1016/0014-2964(77)90017-2. [DOI] [PubMed] [Google Scholar]
- Luce J. K. Chemotherapy of malignant melanoma. Cancer. 1972 Dec;30(6):1604–1615. doi: 10.1002/1097-0142(197212)30:6<1604::aid-cncr2820300629>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
- McIllmurray M. B., Embleton M. J., Reeves W. G., Langman M. J., Deane M. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. Br Med J. 1977 Feb 26;1(6060):540–542. doi: 10.1136/bmj.1.6060.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McNeer G., Cantin J. Local failure in the treatment of melanoma. The Janeway lecture, 1966. Am J Roentgenol Radium Ther Nucl Med. 1967 Apr;99(4):791–808. doi: 10.2214/ajr.99.4.791. [DOI] [PubMed] [Google Scholar]
- Newlands E. S., Oon C. J., Roberts J. T., Elliott P., Mould R. F., Topham C., Madden F. J., Newton K. A., Westbury G. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer. 1976 Aug;34(2):174–179. doi: 10.1038/bjc.1976.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pinsky C. M., Hirshaut Y., Wanebo H. J., Fortner J. G., Miké V., Schottenfeld D., Oettgen H. F. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma. Ann N Y Acad Sci. 1976;277(00):187–194. doi: 10.1111/j.1749-6632.1976.tb41697.x. [DOI] [PubMed] [Google Scholar]
- Vaage J. Influence of tumor antigen on maintenance versus depression of tumor-specific immunity. Cancer Res. 1973 Mar;33(3):493–503. [PubMed] [Google Scholar]